The DOI matches its Crossref record.
Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease
Abstract
AIMS: MicroRNA-126 (miR-126) facilitates angiogenesis and regulates endothelial cell function. Recent data suggest that miR-126 can serve as a biomarker for vascular disease. Although endothelial cells are enriched for miR-126, platelets also contain miR-126. In this paper, we investigated the contribution of platelets to the pool of miR-126 in plasma of patients with type 2 diabetes (DM2) and how this is affected by aspirin. METHODS AND RESULTS: In vitro platelet activation resulted in the transfer of miR-126 from the platelet to the plasma compartment, which was prevented by aspirin. In vivo platelet activation, monitored in patients with DM2 by measuring soluble P-selectin, correlated directly with circulating levels of miR-126. The administration of aspirin resulted both in platelet inhibition and concomitantly reduced circulating levels of platelet-derived microRNAs including miR-126. CONCLUSION: Platelets are a major source of circulating miR-126. Consequently, in patho-physiological conditions associated with platelet activation, such as diabetes type 2, the administration of aspirin may lead to reduced levels of circulating miR-126. Thus, the use of platelet inhibitors should be taken into account when using plasma levels of miR-126 as a biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
microRNAs in Cardiovascular Diseases
Condorelli, G., Latronico, M. V. G., & Cavarretta, E. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.050 · Cited by 375
Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury
Viereck, J., & Thum, T. (2017) · Circulation Research · doi:10.1161/circresaha.116.308434 · Cited by 374
Plasma processing conditions substantially influence circulating microRNA biomarker levels
Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064795 · Cited by 317
Jansen, F., Nickenig, G., & Werner, N. (2017) · Circulation Research · doi:10.1161/circresaha.117.310752 · Cited by 280
Challenges in Using Circulating miRNAs as Cancer Biomarkers
Tiberio, P., Callari, M., Angeloni, V., Daidone, M. G., & Appierto, V. (2015) · BioMed Research International · doi:10.1155/2015/731479 · Cited by 271
Metadata
- Authors
- de Boer, H. C., van Solingen, C., Prins, J., Duijs, J. M. G. J., Huisman, M. V., Rabelink, T. J., & van Zonneveld, A. J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-04
- Volume
- 34
- Issue
- 44
- Pages
- 3451-3457
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2148898277
- Cited by
- 165
- References
- 0
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. https://app.cochat.ai/papers/10.1093/eurheartj/eht007
- The paper
- de Boer, H. C., van Solingen, C., Prins, J., Duijs, J. M. G. J., Huisman, M. V., Rabelink, T. J., & van Zonneveld, A. J. (2013). Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. European Heart Journal. https://doi.org/10.1093/eurheartj/eht007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.